The Hydroponics Company Limited (THC) has launched the Endoca Hemp Oil range of products in Australia, through the Medicinal Cannabis Medicines Portal (MCMP) portal; that will see a landmark change in the access to cannabidiol (CBD) for patients in Australia. The Federal and State laws and public perceptions surrounding Medicinal Cannabis in Australia have been notably restrictive over the years.
However, since the announcement of the Medicinal Cannabis framework in 2016, the Therapeutic Goods Administration (TGA) has received and approved an increasing number of requests for Medicinal Cannabis products for a select few suffering with very specific or terminal illnesses.
As the major world players like Europe and America start acknowledging the potential medical benefits of cannabis. Australia has now also decided to follow suit and implement a framework which allows cannabis for medical use, and thereby making it available to a wider range of patients.
In the past Australia’s restrictive approach regarding Medical Cannabis has made it almost impossible for physicians to prescribe and for patients to gain access. However, the Australian Federal Government realised they could no longer take such a hard stance on Medicinal Cannabis products:
CBD and CBD-only products
A selection of our products
From 1 November 2016, further amendments were made to downregulate cannabis for medical use from a Schedule 9 (S9) Prohibited Substances to Schedule 8 (S8) Controlled Drug for certain medicinal cannabis products - cannabis (including seeds, extracts, resins and the plant or any part of the plant) and tetrahydrocannabinol (when extracted from cannabis). However, the scheduling changes remain a decision for individual states/territories to include in their legislation for medicinal cannabis.
Since 30 July 2018, the TGA have also implemented the online Special Access Scheme (SAS) to streamline the application processes for practitioners to access CBD and medicinal cannabis for their patients. The new SAS online system allows prescribing doctors in certain States /Territories to submit an application to both the Federal and relevant State/Territory Health Departments at the same time. Prior to the introduction of this system, prescribers of unapproved medicinal cannabis products were required to complete and separately submit paper forms
For those that have been advocating for the use of cannabis for medical use in Australia, this is a big step forward.
Endoca Partners with Hydroponics
Endoca has partnered with The Hydroponics Company Ltd to make their unique formulations of CBD and CBD+CBDA products available to Australian prescribers and patients.
The Hydroponics Company Ltd, will supply the Endoca Hemp Oil range of products for medicinal use in Australia.
THC is quickly becoming the leading company for medical cannabis in Australia and aims to provide high-quality medicinal cannabis to patients.
THC’s CEO Ken Charteris has said:
“We are pleased to now be delivering high-quality medicinal cannabis products to the Australian market through MCMP having leveraged our global commercial partnerships, including Endoca and Sinapse.’
THC is advancing its medicinal cannabis strategy, with the capacity to grow and manufacturer GMP grade medicinal cannabis in its facilities. To date, no commercial company has been granted a license to grow cannabis for medicinal purposes under legislation that commenced on 30 October 2017; however, the Federal Department of Health is currently receiving and assessing applications.
THC CEO Ken Charteris has said:
“Bringing product to the Australian market is a key step in the execution of our medicinal cannabis strategy, with imported product to be followed by THC’s domestic production taking advantage of our industry-leading pharmaceuticals manufacturing facility and significant growing capacity.”
THC’s leading industry position in Australia puts it in a prime position to partner with its European strategic alliance partner, Endoca, and import CBD and CBD+CBDA products to Australia where it will supply practitioners and patients with one of the highest qualities of CBD product.
The Medicinal Cannabis Medicines Portal (MCMP) is an online portal that provides a system that connects prescribers, pharmacists, patients and suppliers. The MCMP allows prescribers and pharmacists to register and gain information on, how and where they can access Endoca CBD products; and for patients it provides details of prescribers, community pharmacies and details of who has expressed an interest in the topic of Medicinal Cannabis, and are happy for their details to be made available to the public. These healthcare professionals will be able to assist patients in accessing medicinal cannabis subject to prior compliance with regulatory requirements and the issue of a valid prescription.
THC’s CEO Ken Charteris has said:
“Using MCMP reduces the administrative burden on prescribing doctors and pharmacies, which is currently a key challenge for the prescribing of medicinal cannabis in Australia.
“We look forward to seeing the first patients using product supplied by THC in the coming weeks.”
Endoca Hemp Oil range products are available on private prescription-only, by Medical Practitioners that are registered. The MCMP provides information on how to find a doctor that is registered, and which pharmacies will be participating in the scheme.
There is a strong advocacy among Australians that Medical Cannabis should be available to those that need it. This partnership, the SAS online system and the MCMP portal are huge steps forward to streamline a once notably challenging system for accessing Medicinal Cannabis.
The recent TGA “Medicinal cannabis - guidance documents” provide doctors with clinical evidence to support their decision on who will be eligible for Medicinal Cannabis.
Availability to those that do qualify could be potentially life-changing and is sure to inspire even more changes in the ever-developing medical cannabis landscape.